Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ:SNDX
RESEARCH TOOLSreports
Syndax Pharmaceuticals (SNDX) Stock Price & Analysis
551 Followers
SNDX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.22 - $25.34
Previous Close$20.49
Volume118.53K
Average Volume (3M)1.18M
Market Cap
$1.77B
Enterprise Value$1.17B
Total Cash (Recent Filing)$570.70M
Total Debt (Recent Filing)$1.61M
Price to Earnings (P/E)-6.9
Beta1.09
Next Earnings
May 06, 2024EPS Estimate
-$0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.96
Shares Outstanding84,965,486
10 Day Avg. Volume851,239
30 Day Avg. Volume1,177,317
Standard Deviation0.17
R-Squared0.10
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)3.26
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-10.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.12
Forecast
1Y Price Target
$33.63Price Target Upside61.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Syndax Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive topline data from the AUGMENT-101 trial showing a 23% CR/CRh rate.
Drug Approval ProcessSyndax received FDA priority review for its NDA for revumenib, with a PDUFA action date set.
Revenue ForecastAnalyst projects revenues of $548 million for revumenib in AML/ALL by 2028.
Bears Say
Clinical Development ConcernsConcerns on the ability to layer on additional AML/ ALL therapies due to overlapping adverse events.
Downward Earnings RevisionThe analyst has significantly lowered the EPS estimate for the upcoming fiscal year, reflecting a more pessimistic financial outlook for the company.
Earnings MissSyndax reported an EPS significantly below analyst's and consensus estimates, suggesting financial performance concerns.
---
Ownership Overview
1.05% Insiders
20.52% Mutual Funds
14.65% Other Institutional Investors
63.78% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SNDX FAQ
What was Syndax Pharmaceuticals Inc’s price range in the past 12 months?
Syndax Pharmaceuticals Inc lowest stock price was $11.21 and its highest was $25.34 in the past 12 months.
What is Syndax Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Syndax Pharmaceuticals Inc’s upcoming earnings report date?
Syndax Pharmaceuticals Inc’s upcoming earnings report date is May 06, 2024 which is in 11 days.
How were Syndax Pharmaceuticals Inc’s earnings last quarter?
Syndax Pharmaceuticals Inc released its earnings results on Feb 27, 2024. The company reported -$1 earnings per share for the quarter, missing the consensus estimate of -$0.968 by -$0.032.
Is Syndax Pharmaceuticals Inc overvalued?
According to Wall Street analysts Syndax Pharmaceuticals Inc’s price is currently Undervalued.
Does Syndax Pharmaceuticals Inc pay dividends?
Syndax Pharmaceuticals Inc does not currently pay dividends.
What is Syndax Pharmaceuticals Inc’s EPS estimate?
Syndax Pharmaceuticals Inc’s EPS estimate is -$0.99.
How many shares outstanding does Syndax Pharmaceuticals Inc have?
Syndax Pharmaceuticals Inc has 84,965,485 shares outstanding.
What happened to Syndax Pharmaceuticals Inc’s price movement after its last earnings report?
Syndax Pharmaceuticals Inc reported an EPS of -$1 in its last earnings report, missing expectations of -$0.968. Following the earnings report the stock price went down -2.171%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc?
Among the largest hedge funds holding Syndax Pharmaceuticals Inc’s share is Woodline Partners LP. It holds Syndax Pharmaceuticals Inc’s shares valued at 33M.
---
Syndax Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.63 (61.76% Upside)
$33.63 (61.76% Upside)
Blogger Sentiment
Bullish
SNDX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.56%
12-Months-Change
Fundamentals
Return on Equity
-40.98%
Trailing 12-Months
Asset Growth
23.26%
Trailing 12-Months
Company Description
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
---
SNDX Company Deck
---
SNDX Earnings Call
Q4 2024
0:00 / 0:00
---
SNDX Stock 12 Months Forecast
Average Price Target
$33.63
▲(61.76% Upside)
Technical Analysis
Best Analysts Covering SNDX
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
+9.73%
reiterated a buy rating 2 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +9.73% per trade.
---